Biotherapeutics Cell Line Development Market Driven By Growth In The Biopharmaceutical Industry

Over the past few years, the demand for biotherapeutics has witnessed a significant rise, thanks to the increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, cancer, and multiple sclerosis. This growth in the demand for biotherapeutics, together with the imminent launch of several biopharmaceutical drugs, has created a substantial demand for cell line development.

On the other hand, the strict rules and policies, regulating cell culture procedures in the production of biotherapeutics are creating difficulties for participants in their business expansion. However, unmet medical needs in emerging economies of Asia Pacific, Latin America, and Africa, is expected to provide lucrative opportunities for market players over the next few years.

The global market for is estimated to with the opportunity in biotherapeutics cell line development will rise from US$56 mn in 2014 to nearly US$100 mn by 2022, rising at a CAGR of 7.50% between 2015 and 2022.

Request free Sample pages of premium Research Report: http://bit.ly/2cWGynC

A high degree of consolidation is the defining feature of the competitive landscape of the global biotherapeutics cell line development market, finds Transparency Market Research. Becton Dickinson and Co. and Beckman Coulter, the top two companies operating in the biotherapeutics cell line development market, accounted for 85% of the overall market in 2015.

This consolidation has led to reduced market shares for other players and has also abated the possibility of new entrants, thereby offering prominent opportunities for business expansion existing leaders. Over the coming years, these players will need to focus on advancements in technologies to gain a competitive edge over each other.

Unmet Medical Needs in Emerging Economies to Present Lucrative Opportunities for Biotherapeutics Cell Line Development

The increasing prevalence of chronic diseases, stimulated by the rapid growth of the global geriatric population, has created favorable conditions for the progression of biotherapeutics. Currently, the increasing percentage of elderly individuals in the world’s population is a significant trend, which is likely to intensify over the years to come. This rise in geriatric population is impelling the incidence of chronic, degenerative, and autoimmune diseases such as diabetes, cancer, and multiple sclerosis. Biotherapeutics, supported by its high efficiency, is grabbing substantial attention from patients as well as medical professionals for the treatment of these diseases, leading to a significant thrust to the development of biotherapeutics cell line across the world.

Looking forward, emerging economies in Asia Pacific, Latin America, and Africa, laden with unmet medical needs, will provide lucrative opportunities for biotherapeutics cell line development over the next few years. Apart from this, the growing demand for monoclonal antibodies is also projected to stimulate development activities for these cell lines in the near future.

Stringent Regulations Could Delay Product Development, Hamper Market Growth

Although the market for biotherapeutics cell line development looks thriving at present, the stringent norms and policies that regulate cell culture procedures in the production of biotherapeutics create severe issues for market participants.

As the development of stable cell line producing biologics needs to follow standard operating procedures and compliance, and requires to monitor product quality by performing tests in line with SOPs and regulations, existing players face delay in product development. These regulations also restrict the entry of new players in this market.

Single Cell Cloning to Remain Most Preferred Process for Cell Line Development

The global market for biotherapeutics cell line development is estimated to expand at a steady CAGR of 7.50% during the period from 2015 to 2022, with the opportunity rising from US$56.03 mn in 2014 to US$99.8 mn by the end of the forecast period.

North America has been leading this market since the last few years and is projected to remain the key revenue contributor in the near future. The region is likely to witness a rise in its market opportunity from US$23.5 mn in 2014 to US$41 mn by 2022. However, Asia Pacific is anticipated to report the fastest CAGR of 9.40% during the forecast period.

Single cell cloning was the main cell line development process followed in 2014. Analysts expect it to continue to lead with a majority share throughout the forecast period. Outsourcing will emerge as the most preferred cell line development option for biotherapeutics over the forthcoming years, states TMR.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.